Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.38 |
| ▸ | CDK9 | P50750 | 3/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242681 | 1.00 | PDE4B (0.44) | PDE4BCCNT1CDK9NR1H2LIPE | |
| SCHEMBL4246769 | 0.87 | NR1H2 (0.38) | PDE4BNR1H2LIPEUSP30BTK | |
| SCHEMBL4246712 | 0.83 | PDE4B (0.45) | PDE4BCCNT1CDK9LIPEUSP30 | |
| SCHEMBL4245207 | 0.74 | USP30 (0.41) | PDE4BNR1H2LIPEUSP30BTK | |
| SCHEMBL31503237 | 0.72 | MAPK1 (0.47) | PDE4BNR1H2LIPEUSP30BTK | |
| SCHEMBL19272699 | 0.72 | NR1H2 (0.49) | PDE4BNR1H2LIPEUSP30BTK | |
| SCHEMBL15012086 | 0.72 | NR1H2 (0.49) | PDE4BNR1H2LIPEUSP30BTK | |
| SCHEMBL2355843 | 0.72 | NR1H2 (0.49) | PDE4BNR1H2LIPEUSP30BTK | |
| SCHEMBL4482316 | 0.71 | CHRNA4 (0.33) | — | |
| SCHEMBL30271952 | 0.71 | PDE4B (0.47) | PDE4BUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618980-B2 | Pyrrolo(oxo)quinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1773833-A4 | PYRROLO(OXO)QUINOLINES AS 5HT LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1773833-A2 | PYRROLO(OXO)QUINOLINES AS 5HT LIGANDS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006019940-A2 | PYRROLO(OXO)QUINOLINES AS 5HT LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014778-A1 | (+-)-cis 6-Methoxy-8-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,4-c]quinoline; serotonin receptor modulators; obesity, diabetes, atherosclerosis, dyslipidemia; central nervous system diseases like anxiety, depression, OCD, panic disorder, psychosis, schizophrenia, sleep and sexual disorders, | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014778-A1 | (+-)-cis 6-Methoxy-8-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,4-c]quinoline; serotonin receptor modulators; obesity, diabetes, atherosclerosis, dyslipidemia; central nervous system diseases like anxiety, depression, OCD, panic disorder, psychosis, schizophrenia, sleep and sexual disorders, | HTR3B, HTR2C, HTR2B | PDE4B 517/4885CCNT1 4355/4885CDK9 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.